The global pancreatic cancer precision medicine market size is calculated at USD 823.30 million in 2025 and is forecasted to reach around USD 4,030.16 million by 2034, accelerating at a CAGR of 19.30% from 2025 to 2034. The North America market size surpassed USD 296.75 billion in 2024 and is expanding at a CAGR of 19.43% during the forecast period. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Pancreatic Cancer Precision Medicine Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Pancreatic Cancer Precision Medicine Market Revenue and Volume, By Therapeutic Approach
8.1.1 Targeted Therapy
8.1.1.1. Market Revenue and Volume Forecast
8.1.2. PARP Inhibitors
8.1.2.1. Market Revenue and Volume Forecast
8.1.3. Monoclonal Antibodies
8.1.3.1. Market Revenue and Volume Forecast
8.1.4. Small Molecule Inhibitors - EGFR Inhibitors, KRAS Inhibitors
8.1.4.1. Market Revenue and Volume Forecast
8.1.5. Immunotherapy
8.1.5.1. Market Revenue and Volume Forecast
8.1.6. Immune Checkpoint Inhibitors - PD-1 Inhibitors, PD-L1 Inhibitors
8.1.6.1. Market Revenue and Volume Forecast
8.1.7. Cancer Vaccines - GVAX, Algenpantucel-L
8.1.7.1. Market Revenue and Volume Forecast
8.1.8. Adoptive T-Cell Therapies - CAR-T therapies
8.1.8.1.Market Revenue and Volume Forecast
8.1.9. Chemotherapy-Precision Combinations
8.1.9.1. Market Revenue and Volume Forecast
8.1.10. Other Therapeutic Approaches
8.1.10.1. Market Revenue and Volume Forecast
9.1. Pancreatic Cancer Precision Medicine Market Revenue and Volume, By Diagnostic Technology
9.1.1. Genomic Testing
9.1.1.1. Market Revenue and Volume Forecast
9.1.2. Molecular Diagnostics
9.1.2.1. Market Revenue and Volume Forecast
9.1.3. Liquid Biopsy
9.1.3.1. Market Revenue and Volume Forecast
9.1.4. Biomarker-based Companion Diagnostics
9.1.4.1. Market Revenue and Volume Forecast
9.1.5. Others (Immunohistochemistry (IHC), Proteomics, Mass Spectrometry)
9.1.5.1. Market Revenue and Volume Forecast
10.1. North America
10.1.1. Market Revenue and Volume Forecast, By Therapeutic Approach
10.1.2. Market Revenue and Volume Forecast, By Diagnostic Technology
10.1.3. U.S.
10.1.3.1. Market Revenue and Volume Forecast, By Therapeutic Approach
10.1.3.2. Market Revenue and Volume Forecast, By Diagnostic Technology
10.1.4. Rest of North America
10.1.4.1. Market Revenue and Volume Forecast, By Therapeutic Approach
10.1.4.2. Market Revenue and Volume Forecast, By Diagnostic Technology
10.2. Europe
10.2.1. Market Revenue and Volume Forecast, By Therapeutic Approach
10.2.2. Market Revenue and Volume Forecast, By Diagnostic Technology
10.2.3. UK
10.2.3.1. Market Revenue and Volume Forecast, By Therapeutic Approach
10.2.3.2. Market Revenue and Volume Forecast, By Diagnostic Technology
10.2.4. Germany
10.2.4.1. Market Revenue and Volume Forecast, By Therapeutic Approach
10.2.4.2. Market Revenue and Volume Forecast, By Diagnostic Technology
10.2.5. France
10.2.5.1. Market Revenue and Volume Forecast, By Therapeutic Approach
10.2.5.2. Market Revenue and Volume Forecast, By Diagnostic Technology
10.2.6. Rest of Europe
10.2.6.1. Market Revenue and Volume Forecast, By Therapeutic Approach
10.2.6.2. Market Revenue and Volume Forecast, By Diagnostic Technology
10.3. APAC
10.3.1. Market Revenue and Volume Forecast, By Therapeutic Approach
10.3.2. Market Revenue and Volume Forecast, By Diagnostic Technology
10.3.3. India
10.3.3.1. Market Revenue and Volume Forecast, By Therapeutic Approach
10.3.3.2. Market Revenue and Volume Forecast, By Diagnostic Technology
10.3.4. China
10.3.4.1. Market Revenue and Volume Forecast, By Therapeutic Approach
10.3.4.2. Market Revenue and Volume Forecast, By Diagnostic Technology
10.3.5. Japan
10.3.5.1. Market Revenue and Volume Forecast, By Therapeutic Approach
10.3.5.2. Market Revenue and Volume Forecast, By Diagnostic Technology
10.3.6. Rest of APAC
10.3.6.1. Market Revenue and Volume Forecast, By Therapeutic Approach
10.3.6.2. Market Revenue and Volume Forecast, By Diagnostic Technology
10.4. MEA
10.4.1. Market Revenue and Volume Forecast, By Therapeutic Approach
10.4.2. Market Revenue and Volume Forecast, By Diagnostic Technology
10.4.3. GCC
10.4.3.1. Market Revenue and Volume Forecast, By Therapeutic Approach
10.4.3.2. Market Revenue and Volume Forecast, By Diagnostic Technology
10.4.4. North Africa
10.4.4.1. Market Revenue and Volume Forecast, By Therapeutic Approach
10.4.4.2. Market Revenue and Volume Forecast, By Diagnostic Technology
10.4.5. South Africa
10.4.5.1. Market Revenue and Volume Forecast, By Therapeutic Approach
10.4.5.2. Market Revenue and Volume Forecast, By Diagnostic Technology
10.4.6. Rest of MEA
10.4.6.1. Market Revenue and Volume Forecast, By Therapeutic Approach
10.4.6.2. Market Revenue and Volume Forecast, By Diagnostic Technology
10.5. Latin America
10.5.1. Market Revenue and Volume Forecast, By Therapeutic Approach
10.5.2. Market Revenue and Volume Forecast, By Diagnostic Technology
10.5.3. Brazil
10.5.3.1. Market Revenue and Volume Forecast, By Therapeutic Approach
10.5.3.2. Market Revenue and Volume Forecast, By Diagnostic Technology
10.5.4. Rest of LATAM
10.5.4.1. Market Revenue and Volume Forecast, By Therapeutic Approach
10.5.4.2. Market Revenue and Volume Forecast, By Diagnostic Technology
11.1. AstraZeneca
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. Pfizer Inc
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. Novartis AG
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. Amgen Inc.
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. Recent Initiatives
11.5. F. Hoffmann-La Roche Ltd
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. Bayer AG
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. Eli Lilly and Company
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. Merck & Co., Inc.
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
11.9. Teva Pharmaceutical Industries Ltd
11.9.1. Company Overview
11.9.2. Product Offerings
11.9.3. Financial Performance
11.9.4. Recent Initiatives
11.10. PharmaCyte Biotech, Inc.
11.10.1. Company Overview
11.10.2. Product Offerings
11.10.3. Financial Performance
11.10.4. Recent Initiatives
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
13.1. About Us
13.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
Plan your call and get expert insights!
Schedule a Meeting
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample